Janux Therapeutics(US:JANX)2025-11-06 21:10Financial Performance - Janux reported a net loss of $24.3 million for Q3 2025, an improvement from a net loss of $28.1 million in Q3 2024, reflecting a reduction of approximately 13%[6] - Collaboration revenue for Q3 2025 was $10.0 million, significantly higher than $439,000 in Q3 2024[14] - Total operating expenses for Q3 2025 were $45.3 million, compared to $36.3 million in Q3 2024, marking an increase of 25%[14] Cash and Assets - Janux reported cash, cash equivalents, and short-term investments of $989.0 million as of September 30, 2025, down from $1.03 billion at December 31, 2024, representing a decrease of approximately 4%[6] - Janux's total assets decreased to $1.025 billion as of September 30, 2025, from $1.062 billion at December 31, 2024, indicating a decline of approximately 3.5%[12] Expenses - Research and development expenses for Q3 2025 were $34.6 million, an increase of 86% compared to $18.6 million for the same period in 2024[6] - General and administrative expenses for Q3 2025 were $10.6 million, a decrease of 40% from $17.7 million in Q3 2024[6] Clinical Development - The company continues to enroll patients in the first-in-human Phase 1 clinical trials for JANX007 and JANX008, with updates expected in Q4 2025[5] - Janux is advancing additional CD3-based TRACTr and CD28-based TRACIr programs for future clinical development, including a PSMA-TRACIr and a TROP2-TRACTr[7] Share Information - The weighted-average shares of common stock outstanding for Q3 2025 were 62,023,685, compared to 54,628,670 in Q3 2024[14]